1-2 of 2
Kristy R. Bodden
Close
Sort by
Journal Articles

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

Kiyomi Morita, MDPhD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Kristy R. Bodden, Feng Wang, PhD, Prithviraj Bose, MD, Yesid Alvarado, MD, Naval Daver, MD, Gautam Borthakur, MD, Farhad Ravandi, MBBS, Koichi Takahashi, MD PhD, Elias Jabbour, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Mohammad Azab, MD MSc, MBA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-140614
Published: 2020
Journal Articles

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

Guillermo Garcia-Manero, MD, Koji Sasaki, MD, Guillermo Montalban-Bravo, MD, Kristy R. Bodden, Prithviraj Bose, MD, Yesid Alvarado, MD, Naval G. Daver, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Koichi Takahashi, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Kiran Naqvi, MDMPH, Courtney D. DiNardo, MDMSc, Christopher B. Benton, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Maro N. Ohanian, DO, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 232.
https://doi.org/10.1182/blood-2018-99-116838
Published: 2018